Evidence map›Paper›PMID 27542958›Full record

ArticleAnnals of hematology2016

BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.

Andrea Haerzschel, Julie Catusse, Evelyn Hutterer, Manuela Paunovic, Katja Zirlik, Hermann Eibel, Peter W Krenn, Tanja N Hartmann, Meike Burger

Open access · hybridAbstract read
In one paragraph

Article in Annals of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Andrea HaerzschelFreiburg University Medical Center, Department of Hematology and Oncology, Albert-Ludwigs-University Freiburg, Breisgau, Germany.
Julie CatusseFreiburg University Medical Center, Department of Hematology and Oncology, Albert-Ludwigs-University Freiburg, Breisgau, Germany.
Evelyn HuttererLaboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Manuela PaunovicLaboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Katja ZirlikFreiburg University Medical Center, Department of Hematology and Oncology, Albert-Ludwigs-University Freiburg, Breisgau, Germany.
Hermann EibelCenter for Chronic Immunodeficiency (CCI), University Medical Center and University Freiburg, Freiburg, Germany.
Peter W KrennLaboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
Tanja N HartmannLaboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria. t.hartmann@salk.at.
Meike BurgerFreiburg University Medical Center, Department of Hematology and Oncology, Albert-Ludwigs-University Freiburg, Breisgau, Germany.
Paracelsus Medical University · ATFurtwangen University · DEUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulation of B cell receptor (BCR) signalling is a hallmark of chronic lymphocytic leukaemia (CLL) pathology, and targeting BCR pathway kinases has brought great therapeutic advances. Activation of the BCR in lymphoid organs has been associated with CLL cell proliferation and survival, leading to progressive disease. While these responses are mediated predominantly by IgM, the role of IgD is less clear. Seeking to uncover downstream consequences of individual and combined stimulation of the two BCR isotypes, we found an amplification of IgD expression and IgD-mediated calcium signalling by previous stimulation of IgM in CLL. Furthermore, no heterologous downmodulation of the isotypes, as observed in healthy donors, was present. Only marginal downregulation of the expression of various chemokine receptors by α-IgM and α-IgD stimulation was found as compared to normal B cells. Consistently, calcium responses of CLL cells to different chemokines were only weakly affected by preceding BCR activation. In contrast, migration towards the two homeostatic chemokines CXCL12 and CCL21 was differentially regulated by IgM and IgD. While IgM activation reduced migration of CLL cells towards CXCL12, but not CCL21, IgD activation predominantly impacted on CCL21 but not CXCL12-mediated chemotaxis. This indicates that the preference for one chemokine over the other may depend on the functional presence of the two isotypes in CLL. Inhibitors against the kinases Syk, Lyn, and Btk antagonised both BCR- and chemokine-induced calcium signals.

Indexed as

Antibodies, Anti-IdiotypicChemokine CCL21Chemokine CXCL12ChemokinesHumansLeukemia, Lymphocytic, Chronic, B-CellReceptors, Antigen, B-CellTumor Cells, CulturedAntibodies, Anti-Idiotypicanti-IgDanti-IgMCCL21 protein, humanChemokine CCL21Chemokine CXCL12ChemokinesCXCL12 protein, humanReceptors, Antigen, B-CellBCR signallingChemokinesCLLIgDIgM

Identifiers

PMID27542958
PMCPMC5093209
OpenAlexW2517405802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.